CELG

Celgene Share Price - CELG

108.24
0.00 (0.0%)
Upgrade to Real-Time
Regular Market
108.24
Best deals to access real time data!
USA CHART Trader
Monthly Subscription
for only
US$30.66
North American Extreme
Monthly Subscription
for only
US$104.50
USA Small Cap Basic
Monthly Subscription
for only
US$33.03
VAT not included
Stock Name Stock Symbol Market Stock Type
Celgene Corporation CELG NASDAQ Common Stock
  Price Change Price Change % Stock Price Last Trade
0.00 0.0% 108.24 19:00:00
Low Price High Price Open Price Previous Close
0.00 0.00 0.00 108.24
Bid Price Ask Price Spread News
109.30 109.37 0.07 - -
Last Trade Type Quantity Price Currency
- 0 US$ 108.24 USD

Celgene Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
US$ 77.04B 711.71M 701.35M US$ - US$ - - 13.40
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- US$ - 0.00% - -

more financials information »

Celgene News

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CELG Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year93.46110.7892.70104.916,261,27914.7815.81%
3 Years132.05147.1758.5993.386,673,752-23.81-18.03%
5 Years131.54147.1758.59100.475,560,492-23.30-17.71%

Celgene Description

Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Recent acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.
Your Recent History
NASDAQ
CELG
Celgene
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200814 16:56:43